Samsung Biologics completes full acquisition of Samsung Bioepis
Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary First payment completed funded through paid-in capital Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON, South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today that it has completed the purchase of Biogen's stake in the Samsung Bioepis joint...
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic. The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the...
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies. This is another milestone after CMG901 received Orphan-drug Designation from the FDA....
MILVIK BIMA RAISES FRESH INVESTMENT FOR DIGITAL HEALTH WALLET TECHNOLOGY
STOCKHOLM, LONDON and SINGAPORE, April 20, 2022 /PRNewswire/ -- MILVIK BIMA ("BIMA"), a leading digital healthcare solutions provider in emerging markets, has raised new funds from existing shareholders Allianz X and Leapfrog Investments to launch its Health Wallet in Asia. Snapshot of the BIMA Health+ App and Health Wallet The BIMA...
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 20, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor cobimetinib, to evaluate the safety and efficacy of this combo strategy. ...
Treadwell Therapeutics Announces the Appointment of J.D. Mowery, as Chief Operating Officer
NEW YORK and HONG KONG, April 20, 2022 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced today the appointment of J.D. Mowery as Chief Operating Officer (COO). Reporting into the office of the CEO, J.D. will play an integral role in the continued evolution of Treadwell Therapeutics, leveraging...
FIRST PATIENT WITH BASAL CELL CARCINOMA TREATED IN NEW FOCUSED ULTRASOUND STUDY: TOOsonix A/S
The dermatology departments at Bispebjerg and Roskilde Hospitals, University of Copenhagen, Denmark, initiate pioneering treatment of the world's most common cancer with a new convenient, minimal-pain and easy-to-operate modality for skin oncology. HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell...
Excelra Makes Strategic Investment in Anlitiks, a Disruptive HEOR and RWE Technology-led Consulting Company
HYDERABAD, India and BOSTON, Mass., April 19, 2022 /PRNewswire/ -- Excelra, a leading global Data and Analytics provider for Life Science organizations, has announced a strategic majority investment in Anlitiks, a young and rapidly growing technology company in the value and evidence domain. The investment reinforces Excelra's push into the Health Economics...
Mission Bio Partners with S2 Genomics to Offer Robust Solid Tumor Sample Prep for Single-Cell DNA Analysis
MSKCC lab paired Tapestri and Singulator 100 to demonstrate automated nuclei extraction workflow for fast and reliable nuclei prep for single-cell DNA analysis SOUTH SAN FRANCISCO, Calif., April 19, 2022 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced a co-marketing partnership with S2 Genomics, Inc.,...
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination GAITHERSBURG, Md., April 19, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and...
